Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HS-110 |
Synonyms | |
Therapy Description |
HS-110 (viagenpumatucel-L) is a tumor cell vaccine comprised of irradiated tumor cells expressing recombinant gp96-Ig, which is secreted and induces an immune response to endogenous tumor cells (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HS-110 | Viagenpumatucel-L|AD100-gp96-Ig-HLA A1 | HS-110 (viagenpumatucel-L) is a tumor cell vaccine comprised of irradiated tumor cells expressing recombinant gp96-Ig, which is secreted and induces an immune response to endogenous tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02439450 | Phase I | HS-110 Nivolumab | A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | Completed | USA | 0 |